Epifix denied due to quantity / dose limits by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for epifix are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Limits Quantities of EpiFix — and Why You Can Appeal

EpiFix is a dehydrated human amnion/chorion membrane (dHACM) allograft used to support wound healing in chronic wounds such as diabetic foot ulcers and venous leg ulcers. BlueCross BlueShield plans frequently impose quantity limits on EpiFix applications, restricting the number of applications covered within a defined treatment window. These limits are set by BCBS's internal medical and coverage policies, not by a universal clinical standard, and they do not automatically reflect your specific wound's complexity or healing trajectory.

## Why This Denial Is Appealable

Quantity-limit denials are among the most successfully overturned denial types when the clinical record clearly demonstrates that the wound has not reached a healing endpoint and that continued application is medically necessary. If your wound remains open, has not achieved closure milestones expected at this stage, or has characteristics that slow healing (infection history, tissue quality, perfusion issues), the treating clinician's documented judgment that further applications are required is powerful appeal evidence.

## Your Federal Appeal Rights

• Internal appeal: You have the right under ACA §2719 and ERISA §503 to a full-and-fair internal review. Submit within the timeframe stated in your denial letter (typically 180 days).
• External review: If the internal appeal fails, you may request independent external review. For most ACA-compliant and ERISA plans, this window is approximately four months from the final internal denial.
• Expedited review: If delaying further wound care would seriously jeopardize your health or ability to function, request an expedited review, which must be resolved within 72 hours.

## Documentation to Gather

1. Wound documentation: Serial wound measurements (length, width, depth) with photographs showing the wound has not closed and continues to require active treatment. 2. Treatment history with dates and outcomes: Records of all prior wound-care modalities tried, how long each was used, and the clinical response (or lack of response). 3. Diagnosis confirmation: Operative or clinical notes confirming the wound diagnosis, etiology, and any complicating factors. 4. Clinical severity in the chart: Notes describing wound bed quality, exudate, signs of infection, vascular status, or other factors that explain why healing is prolonged. 5. Prescriber medical-necessity letter: A letter from your wound-care specialist or surgeon stating why the number of applications requested is clinically required and what outcome is expected if the limit is enforced.

## Criteria-Mapping Structure

Obtain BCBS's published coverage/medical policy for amniotic membrane allografts (available on the BCBS plan's provider or member portal). For each quantity criterion listed in that policy:

| Policy Requirement | Supporting Chart Evidence | |---|---| | Wound meets covered diagnosis | [Clinical note confirming diagnosis and etiology] | | Prior standard care attempted | [List of therapies with dates and documented outcomes] | | Wound not closed after prior applications | [Serial measurements with dates] | | Continued medical necessity documented | [Prescriber letter + progress notes] |

Present this table in your appeal letter so the reviewer can match each requirement to a specific document in your record.